San Diego, CA, United States of America

Shuichan Xu

USPTO Granted Patents = 26 

 

 

Average Co-Inventor Count = 5.9

ph-index = 7

Forward Citations = 188(Granted Patents)


Company Filing History:


Years Active: 2015-2025

Loading Chart...
Loading Chart...
Loading Chart...
26 patents (USPTO):Explore Patents

Title: **Shuichan Xu: Innovator in Pharmaceutical Compounds**

Introduction

Shuichan Xu, based in San Diego, California, is a prominent inventor with a remarkable portfolio comprising 25 patents. His work primarily focuses on pharmaceutical compounds, contributing significantly to the field of medicinal chemistry and treatment methodologies.

Latest Patents

Shuichan Xu's recent patents showcase his innovative approaches to compound development. His latest inventions include:

1. **Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith** - This patent presents novel piperidine dione compounds with specific structural attributes for therapeutic uses.

2. **Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith** - This invention describes aminopurine compounds featuring defined structures, aimed at enhancing treatment options in various medical fields.

Career Highlights

Throughout his career, Shuichan Xu has been associated with leading pharmaceutical companies. Notable among them are Signal Pharmaceuticals, Inc. and Celgene Corporation, where he has played a critical role in advancing drug development processes.

Collaborations

Shuichan Xu has collaborated with talented individuals such as Tam Minh Tran and Heather K Raymon, contributing to a rich exchange of ideas and innovations in the field of pharmaceutical research.

Conclusion

Shuichan Xu's extensive patent portfolio and innovative contributions reflect his dedication to advancing healthcare solutions. His work continues to inspire and pave the way for future inventions in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…